Valuation check: RPRX's profit margin is 33.9%, above the Healthcare sector average of 15.29%.
Get informed when a big investor buys or sells
+ FollowAs of Mar 2026
Trailing 12 months ending Mar 2026
As of the most recent data (March 2026), RPRX shows a profit margin of 33.9%. That compares with 48.25% in the prior-year period — down 29.7% year over year. That is above the Healthcare sector average of 15.29%. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, RPRX's profit margin is now 33.9% (was 48.25%) — a 29.7% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Royalty Pharma plc is outperforming or lagging.
The Healthcare sector average profit margin is about 15.29%. Royalty Pharma plc is at 33.9%, which is higher that average. That is roughly 121.6% above the sector mean. Use the comparison chart on this page to see how RPRX stacks up against individual peers as well.
That compares with 48.25% in the prior-year period — down 29.7% year over year. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare Royalty Pharma plc with peers to see if the move is company-specific or sector-wide.
Besides this profit margin page, Stockcircle has Royalty Pharma plc's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect profit margin (currently 33.9%) with ownership activity and broader fundamentals.